Publication: Diagnostic performance of whole-genome sequencing for identifying drug-resistant TB in Thailand
Issued Date
2021-09-01
Resource Type
ISSN
18157920
10273719
10273719
Other identifier(s)
2-s2.0-85113919096
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Journal of Tuberculosis and Lung Disease. Vol.25, No.9 (2021), 754-760
Suggested Citation
P. Kamolwat, D. Nonghanphithak, A. Chaiprasert, S. Smithtikarn, P. Pungrassami, K. Faksri Diagnostic performance of whole-genome sequencing for identifying drug-resistant TB in Thailand. International Journal of Tuberculosis and Lung Disease. Vol.25, No.9 (2021), 754-760. doi:10.5588/ijtld.21.0096 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/77900
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Diagnostic performance of whole-genome sequencing for identifying drug-resistant TB in Thailand
Other Contributor(s)
Abstract
BACKGROUND: Whole-genome sequencing (WGS) is a promising tool for the detection of drug-resistant TB (DR-TB). To date, there have been few comparisons of diagnostic performance of WGS and phenotypic drug susceptibility testing (DST) in DR-TB. METHODS : We compared drug resistance-conferring mutations identified by WGS analysis using TB-Profiler and Mykrobe with phenotypic DST profiles based on the Löwenstein-Jensen proportionmethod using drug-resistant Mycobacteriumtuberculosis (n 537) isolates fromacross Thailand. Based on available phenotypic DST results, diagnostic performance was analysed for resistance against isoniazid, rifampicin, ethambutol (EMB), streptomycin, ethionamide (ETH), kanamycin, capreomycin (CPM), para-aminosalicylic acid, ofloxacin and levofloxacin. RESULT S : High agreement between the two methods was observed for most drugs (.91%), except EMB (57%, 95% CI 53-61) and ETH (70%, 95% CI 66-74). Also, low specificity was observed for EMB (49%, 95% CI 44-54) and ETH (66%, 95% CI 61-71). Sensitivity was high for most drugs (range 83-98%), except CPM (77%, 95% CI 59-88). CONC LU S ION: Low agreement between WGS and phenotypic tests for drug resistance was found for EMB and ETH. The current genomic database is insufficient for the identification of CPM resistance. Challenges remain for routine usage of WGS-based DST, especially for second-line anti-TB drugs.